A human leukocyte antigen imputation study uncovers possible genetic interplay between gut inflammatory processes and autism spectrum disorders

DSpace/Manakin Repository

A human leukocyte antigen imputation study uncovers possible genetic interplay between gut inflammatory processes and autism spectrum disorders
 
Lombardi, Laura; Le Clerc, Sigrid; Wu, Ching-Lien; Bouassida, Jihène; Boukouaci, Wahid; Sugusabesan, Sobika; Richard, Jean-Romain; Lajnef, Mohamed; Tison, Maxime; Le Corvoisier, Philippe; Barau, Caroline; Banaschewski, Tobias; Holt, Rosemary; Durston, Sarah; Persico, Antonio M; Oakley, Bethany; Loth, Eva; Buitelaar, Jan; Murphy, Declan; Leboyer, Marion; Zagury, Jean-François; Tamouza, Ryad
(2023) Translational Psychiatry, volume 13, issue 1, pp. 1 - 13
(Article)
Abstract
Autism spectrum disorders (ASD) are neurodevelopmental conditions that are for subsets of individuals, underpinned by dysregulated immune processes, including inflammation, autoimmunity, and dysbiosis. Consequently, the major histocompatibility complex (MHC)-hosted human leukocyte antigen (HLA) has been implicated in ASD risk, although seldom investigated. By utilizing a GWAS performed by the EU-AIMS ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Psychiatry and Mental health, Biological Psychiatry, Cellular and Molecular Neuroscience, Journal Article
DOI: https://doi.org/10.1038/s41398-023-02550-y
ISSN: 2158-3188
Publisher: Nature Publishing Group
Note: Funding Information: The work was supported by grants from the EU-AIMS (European Autism Interventions) and AIMS-2-TRIALS programs which receive support from Innovative Medicines Initiative Joint Undertaking Grant No. 115300 and 777394, the resources of which are composed of financial contributions from the European Union’s FP7 and Horizon2020 programs, and from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contributions, and AUTISM SPEAKS, Autistica and SFARI; and by the Horizon2020 supported program CANDY Grant No. 847818). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders (IHI-JU2). The work was further supported by the Fondation FondaMental and the LVMH group. Laura Lombardi benefits from a fellowship no. FDM202006011305 from Fondation de la Recherche Médicale (FRM). The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 21/12/2022. Funding Information: The work was supported by grants from the EU-AIMS (European Autism Interventions) and AIMS-2-TRIALS programs which receive support from Innovative Medicines Initiative Joint Undertaking Grant No. 115300 and 777394, the resources of which are composed of financial contributions from the European Union’s FP7 and Horizon2020 programs, and from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contributions, and AUTISM SPEAKS, Autistica and SFARI; and by the Horizon2020 supported program CANDY Grant No. 847818). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders (IHI-JU2). The work was further supported by the Fondation FondaMental and the LVMH group. Laura Lombardi benefits from a fellowship no. FDM202006011305 from Fondation de la Recherche Médicale (FRM). The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 21/12/2022. Publisher Copyright: © 2023, The Author(s).
(Peer reviewed)